ArticleCureus2026
Google Trends Analysis of Interest in Pediatric Myopia-Control Spectacle Lenses Following FDA Authorization of Essilor Stellest.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantify changes in US public interest in pediatric myopia-control spectacle lenses surrounding the U.S. Food and Drug Administration (FDA) authorization of Essilor Stellest (Essilor, Charenton-le-Pont, France) (September 25, 2025).
methodsWeekly U.S. Google Trends relative search volume (RSV) data were collected for 2025 for parent-facing and brand-specific pediatric myopia-control spectacle lens search terms, with MiSight-related searches analyzed as a contemporaneous comparator. Search terms were selected a priori to capture both direct interest in the Stellest product and broader public interest in pediatric myopia-control spectacle lenses. A composite interest index was constructed by averaging RSV values for the following terms: "stellest", "stellest lenses", "essilor", "essilor stellest", "myopia control glasses", "pediatric myopia glasses", and "HALT lens". To account for general seasonality in children's eyewear searches, a baseline index was generated using the mean RSV of "kids glasses", "children's glasses", and "eyeglasses for kids", and a normalized interest ratio (composite ÷ baseline) was calculated. Pre- and post-authorization differences were compared using two-sided p-values.
resultsFrom 2025-01-05 to 2025-10-26 (37 pre- and six post-weeks), mean composite interest rose from 9.39 pre to 18.6 post (absolute +9.21, +98%; p = 0.024). The mean ratio to baseline increased from 0.353 to 0.694 (absolute +0.34, +96.3%; p = 0.016). MiSight-related searches remained stable over the same period, supporting a modality-specific response to Stellest authorization.
conclusionsPublic search interest in pediatric myopia-control spectacle lenses increased markedly following FDA authorization of Essilor Stellest, with normalization suggesting growth beyond seasonal effects. These findings demonstrate increased online search activity surrounding pediatric myopia-control spectacles after authorization, which may help clinicians anticipate heightened patient and parent inquiries, although search interest does not directly reflect awareness, clinical adoption, or prescribing behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.